logo-loader
LON:ONC

Oncimmune

Receive alerts
Market:
LON
Market Cap:
£56.29 m
Price
£0.89
Change
0.00%
52 weeks high
138.50
52 weeks low
77.00

Viewing results 1-20 of 20

Health

Oncimmune Holdings hails latest Spain deal for Lung cancer detection device

Local distributor Sabartech has inked an agreement with Vithas Group, which operates 48 hospitals and medical centres...

on 07/15/2019
Health

Russian drug giant strikes multi-million-pound deal to use Oncimmune’s EarlyCDT Lung cancer test

R-Pharm has the exclusive right to use EarlyCDT Lung in Russia for the next five years, and Oncimmune expects the partnership will generate revenues of at least £5mln...

on 07/04/2019
Health

Oncimmune agrees US$28mln partnership with US firm Biodesix for lung cancer test

The exclusive agreement with US group Biodesix is worth up to US$28mln over five years ...

on 06/28/2019
Health

Oncimmune expects material revenues and profits from enlarged lung cancer study

Commercial terms are being negotiated for the study, which is expected to commence later this year and will last approximately 24 months....

on 06/26/2019
Health

Oncimmune gets lift from Scottish lung cancer study success

Oncimmune is a specialist in the field of immunodiagnostics...

on 06/11/2019
Health

Oncimmune says landmark lung cancer detection study is a success

A total of 12,210 Scots were monitored for two years as part of the Early Cancer Detection Test - Lung Cancer Scotland (ECLS) initiative...

on 06/04/2019
Health

Oncimmune receives regulatory approval from Israel for lung cancer diagnosis kit

Lung cancer kills more people in Israel than any other form of the disease, said the company....

on 05/15/2019
Health

Oncimmune kicks off China study of lung cancer screening device

The company’s chief executive, Dr Adam Hill, told investors: "This study is part of our ongoing programme to support the introduction of EarlyCDT-Lung in China, which is progressing to schedule."...

on 05/10/2019
Health

Oncimmune shares extend losses as it awaits results from key NHS lung cancer screening trial

In results for the six months to 30 November 2018, the AIM-listed firm posted a pre-tax loss of £3.85mln, wider from the £2.83mln loss recorded a year earlier, although revenues rose to £121,000 from £77,000...

on 02/13/2019
Health

Oncimmune reports "encouraging" interim data from NHS lung cancer screening trial

The study, using Oncimmune's Early CDT-Lung test, is the largest randomised trial for the early detection of lung cancer using biomarkers ever conducted....

on 12/06/2016
Health

Oncimmune receives certification for early stage lung cancer test

The early stage cancer testing group has obtained the CE mark for the reagents used in its EarlyCDT-Lung test....

on 07/15/2016
Health

Oncimmune does deals to develop cancer tests

Group says deals will allow it to develop tests to distinguish between malignant and benign cancer...

on 07/04/2016
Health

Oncimmune signs up three more US distributors

The agreements will increase the size of the salesforce across the US selling EarlyCDT-Lung to more than 140 ...

on 05/25/2016
Health

Oncimmune floats on AIM to develop early stage cancer diagnostics

Oncimmune has developed tests that have the potential to detect cancer up to four years earlier than other methods ...

on 05/18/2016
Health

Oncimmune AIM listing for test that detects cancer 'years earlier'

Oncimmune is set to list on London’s AIM with dealings set to commence on 10 May....

on 04/25/2016